Metallated phthalocyanines and their hydrophilic derivatives for multi-targeted oncological photodynamic therapy

Lionel Mendes Dias1, Mark J de Keijzer2, Daniël Ernst3

  • 1Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, Zhejiang, PR China; CICS-UBI, Health Sciences Research Center, University of Beira Interior, Covilhã, Portugal; Department of Medical Biology, Cancer Center Amsterdam, Amsterdam UMC Location Academic Medical Center, Amsterdam, the Netherlands; Laboratory of Experimental Oncology, Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.

Abstract

Insights

Aluminum phthalocyanines (AlPCs) show promise as safe and effective photosensitizers for photodynamic therapy (PDT). These compounds, delivered via interstitially targeted liposomes (ITLs), demonstrated potent tumor cell killing with minimal systemic toxicity, paving the way for advanced cancer treatment.

Area of Science:

  • Nanomedicine and Drug Delivery
  • Photodynamic Therapy (PDT)
  • Cancer Therapeutics

Background:

  • Development of a photosensitizer (PS) delivery platform for comprehensive tumor targeting before photodynamic therapy (PDT).
  • Formulation of interstitially targeted liposomes (ITLs) encapsulating zinc phthalocyanine (ZnPC) and aluminum phthalocyanine (AlPC) for passive tumor microenvironment targeting.
  • Previous studies confirmed ITL uptake by cholangiocarcinoma cells; this study aimed to verify these findings and assess ITL photosensitization of tumor microenvironment and vasculature.

Purpose of the Study:

  • To verify previous findings on ITL uptake in cancer cells.
  • To determine if ITLs can photosensitize cells within the tumor microenvironment and vasculature.
  • To evaluate the safety and efficacy of ZnPC- and AlPC-based ITLs for potential clinical translation.

Main Methods:

  • Utilized flow cytometry and confocal microscopy to assess ITL uptake and PS distribution in various cell types (cancer, endothelial, fibroblasts, macrophages).
  • Verified endothelial cell uptake under flow conditions.
  • Assessed dark toxicity, PDT efficacy, cell death mechanisms, and cell cycle arrest via cell viability assays and flow cytometry. Evaluated systemic and skin phototoxicity in animal models (zebrafish, chicken embryos, mice) and conducted a pilot PDT efficacy study in breast cancer xenografts.

Main Results:

  • Photodynamically active PSs effectively photosensitized both cancer and non-cancerous cells, exhibiting high potency post-PDT.
  • No significant systemic toxicity was observed in zebrafish and chicken embryos.
  • ITL-delivered AlPC(S4) showed no detectable skin phototoxicity, unlike ZnPC variants. Both ZnPC and AlPC ITLs demonstrated comparable and superior tumor-killing efficacy in xenografts compared to other PSs on a per-mole basis.

Conclusions:

  • Aluminum phthalocyanine derivatives (AlPC(S4)) are identified as the safest and most effective PSs for the developed tumor targeting and delivery platform.
  • These third-generation PSs hold potential for multi-compartmental tumor photosensitization.
  • Further in vivo validation is recommended pending clinical transition.